HLB closed higher on the KOSDAQ market on the 16th, driven by strong buying interest. The stock finished the session at 48,350 won, up 6.26% from the previous trading day.

Trading was intense from the opening bell. HLB opened at 44,800 won and at one point during the session surged to 55,900 won, attracting strong investor attention. However, the stock also dipped to a low of 42,250 won, reflecting high volatility. The day's trading volume exceeded 2.96 million shares, with a trading value reaching the 140 billion won range, indicating very active market participation. Its market capitalization remained at around 6.4 trillion won.

The rally was underpinned by improved investor sentiment across the broader biotech sector and inflows of bargain-hunting buying into individual stocks. After fluctuating early in the session, the stock widened its gains as buying momentum intensified heading into the afternoon. Notably, the rebound was accompanied by a surge in trading volume as the stock sought to recover from a recent short-term correction.

Investors are keeping a close watch on HLB's future clinical development progress and changes in sector supply and demand. The securities industry advised that due to the nature of the biotech industry, stock price volatility could increase depending on each company's research and development (R&D) schedule and external variables, and recommended continuously monitoring relevant disclosures and business progress.

On the same day, capital flowed into growth stocks on the KOSDAQ market, lifting some biotech stocks in a broad rally.

[※ This article was written with AI assistance and is not intended as investment advice. Investment decisions and responsibilities lie solely with the investor.]